Gland Pharma
₹3,091
- Market Cap
- ₹50,311Cr.
- P/E Ratio
- 43.9
- P/B Ratio
- 4.91
- EPS (TTM)
- ₹70.41
- Div Yield
- 0.65%
- ROCE
- 15.1%
- ROE
- 10.7%
52W Low: ₹1,57452W High: ₹3,171
At a glance
- Sales have grown 21.0% a year over three years.
- Debt is 0.03× its shareholders’ equity.
From reported financials and exchange prices. Descriptive only, not advice.
Gland_Pharma — Price
Interval
Style
Failed: 503
Scorecard
Market: risk-off · breadth 378/8Minerviniuptrend checks met
90RS Rankvs all stocks, 1–99
bullRSI Regimemomentum range
31 ▲Trend (ADX)trend strength
2/4CAN SLIMprice & volume checks
upSupertrendprice vs trailing line
accum.Volume Flowbuying vs selling volume
Factual technical classifications from price/volume data — research signals, not investment advice. Hover or tap any badge for what it means.
Evenstocks Score
Middle third
Overall
Valuation
Quality
Fundamental
Growth
Investment Checklist
Quick assessment based on key parametersPerformance
N/ATrailing return unavailableValuation
P/E 43.9P/E: 43.9 | P/B: 4.91Growth
GrowingSales CAGR — 3Y: 21% · 1Y: 18%Profitability
ModerateROCE: 15.1% | ROE: 10.7%Key Metrics
Valuation
PEG Ratio 5.49
Price / Sales 7.48x
Price / FCF 93.5x
Book Value ₹629
Margins & returns
Operating Margin 26%
Net Margin 16.8%
Return on Assets 9.1%